BioPharmSignal logoBioPharmSignal

Biotech News

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

Allogene Therapeutics (ALLO)Allogene Therapeutics2026-06-25 13:46 ESTClinical readout

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma (LBCL) 58.3% (7/12) of Patients in the Cema-Cel Arm Achieved Minimal Residual Disease (MRD)

Open original release

Related news

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Announces Planned CEO Succession

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

View all latest news

Allogene Therapeutics

Allogene Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ALLOAllogene Therapeutics2026-06-26 08:46 EST

Allogene Therapeutics Announces Planned CEO Succession

ALLOAllogene Therapeutics2026-06-26 08:46 EST

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

ALLOAllogene Therapeutics2026-06-26 08:46 EST

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

ALLOAllogene Therapeutics2026-06-26 08:46 EST

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

ALLOAllogene Therapeutics2026-06-26 08:46 EST

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States